Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Washburn W., 2007, 234th National ACS Meeting

2006, Diabetes Atlas, 3

Porte D., 2001, Diabetes Metab. Res. Rev., 17, 181, 10.1002/1520-7560(200105/06)17:3<181::AID-DMRR197>3.0.CO;2-1

Kikkawa R., 2000, Br. J. Nutr., 84, S183, 10.1079/096582197388653

Edelman S. V., 1998, Med. Clin. North. Am., 82, 665, 10.1016/S0025-7125(05)70019-5

Donahoe S. M., 2007, JAMA, J. Am. Med. Assoc., 298, 765, 10.1001/jama.298.7.765

Wong N. D., 2007, Am. J. Cardiovasc. Drugs, 7, 259, 10.2165/00129784-200707040-00004

Bertoni A. G., 2007, Diabetes Care

Rotella D. P., 2004, J. Med. Chem., 47, 4111, 10.1021/jm030626a

Mueller G., 2002, Recent Res. Develop. Endocrinol., 3, 199

Saydah S. H., 2004, JAMA, J. Am. Med. Assoc., 291, 335, 10.1001/jama.291.3.335

1998, Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8

1993, N. Engl. J. Med., 329, 977, 10.1056/NEJM199309303291401

Deetjen P., 1992, The Kidney: Physiology and Pathophysiology, 2873

Moe O. W., 2000, The Kidney, 375

Wright E. M., 1993, Soc. Gen. Physiol. Ser., 48, 229

Wright E. M., 1992, Acta Physiol. Scand., Suppl., 146, 201

Mackenzie B., 1996, J. Biol. Chem., 271, 32678, 10.1074/jbc.271.51.32678

Kanai Y., 1994, J. Clin. Invest., 93, 397, 10.1172/JCI116972

Scheepers A., 2004, JPEN, J. Parenter. Enteral Nutr., 28, 364, 10.1177/0148607104028005364

Wright E. M., 2001, Am. J. Physiol. Renal Physiol., 280, F10, 10.1152/ajprenal.2001.280.1.F10

Wallner E. I., 2001, Ren. Fail., 23, 301, 10.1081/JDI-100104714

You G., 1995, J. Biol. Chem., 270, 29365, 10.1074/jbc.270.49.29365

Hediger M. A., 1994, Physiol. Rev., 74, 993, 10.1152/physrev.1994.74.4.993

Wells R. G., 1992, Am. J. Physiol., 263, F459

Kasahara M., 2001, Biochim. Biophys. Acta, 1536, 141, 10.1016/S0925-4439(01)00043-6

Turk E., 1991, Nature, 350, 354, 10.1038/350354a0

van den Heuvel L. P., 2002, Hum. Genet., 111, 544, 10.1007/s00439-002-0820-5

Santer R., 2000, J. Inher. Metab. Dis., 23, 178

Oku A., 1999, Diabetes, 48, 1794, 10.2337/diabetes.48.9.1794

Ehrenkranz J. R. L., 2005, Diabetes Metab. Res. Rev., 21, 31, 10.1002/dmrr.532

Jonas J.-C., 1999, J. Biol. Chem., 274, 14112, 10.1074/jbc.274.20.14112

Dimitrakoudis D., 1992, J. Am. Soc. Nephrol., 3, 1078, 10.1681/ASN.V351078

Rossetti L., 1987, J. Clin. Invest., 79, 1510, 10.1172/JCI112981

2001, Drugs Future, 26, 750, 10.1358/dof.2001.026.08.630958

Arakawa K., 2001, Br. J. Pharmacol., 132, 578, 10.1038/sj.bjp.0703829

Oku A., 2000, Biol. Pharm. Bull., 23, 1434, 10.1248/bpb.23.1434

Adachi T., 2000, Metabolism, 49, 990, 10.1053/meta.2000.7729

Tsujihara K., 1999, J. Med. Chem., 42, 5311, 10.1021/jm990175n

Oku A., 2000, Eur. J. Pharmacol., 391, 183, 10.1016/S0014-2999(00)00016-9

Nawano M., 2000, Am. J. Physiol. Endocrinol. Metab., 278, E535, 10.1152/ajpendo.2000.278.3.E535

Kikuchi, N.; Fujikura, H.; Tazawa, S.; Yamato, T.; Isaji, M.Preparation of Pyrazole Glycoside Compounds as SGLT Inhibitors.PCT Int. Appl. WO2004113359, 2004;

2004, Chem. Abstr., 142, 94061

Fushimi, N.; Yonekubo, S.; Muranaka, H.; Shiohara, H.; Teranishi, H.; Shimizu, K.; Ito, F.; Isaji, M.Preparation of Glucopyranoside Compounds Having Fused Heterocycle as SGLT Inhibitors.PCT Int. Appl. WO2004087727, 2004;

2004, Chem. Abstr., 141, 332411

Fujikura, H.; Nishimura, T.; Katsuno, K.; Isaji, M.Preparation ofD-Glucose Derivatives as Human SGLT2 Inhibitors.PCT Int. Appl. WO2004058790, 2004;

2004, Chem. Abstr., 141, 123854

Fushimi, N.; Ito, F.; Isaji, M.Preparation of Glucopyranosyloxybenzylbenzene Derivatives as Inhibitors of Human SGLT2 (Sodium-Dependent Glucose-Transporter 2), Medicinal Composition Containing the Same, Medicinal Use thereof, and Intermediate for Production thereof.PCT Int. Appl. WO2003011880, 2003;

2003, Chem. Abstr., 138, 153771

Washburn, W. N.Preparation of O-Glucoside Benzamides as Antidiabetic Agents and SGLT2 Inhibitors. US Patent 6,555,519, 2003;

2001, Chem. Abstr., 135, 273164

Washburn, W. N.; Sher, P. M.; Wu, G.Preparation of O-Aryl Glucosides as Antidiabetic Agents and SGLT2 Inhibitors.U.S. Patent 6,683,056, 2004;

2001, Chem. Abstr., 135, 273163

Washburn, W. N.Preparation of O-Pyrazole Glucoside SGLT2 Inhibitors as Antidiabetic Agents.PCT Int. Appl. WO2003020737, 2003;

2003, Chem. Abstr., 138, 221784

Ellsworth, B. A.; Meng, W.; Patel, M.; Girotra, R. N.; Wu, G.; Sher, P. M.; Hagan, D. L.; Obermeier, M. T.; Humphreys, W. G.; Robertson, J. G.; Wang, A.; Han, S.; Waldron, T. L.; Morgan, N. N.; Whaley, J. M.; Washburn, W. N.Unpublished results.

Ellsworth, B.; Washburn, W. N.; Sher, P. M.; Wu, G.; Meng, W.C-Aryl Glucoside SGLT2 Inhibitors and Method.U.S. Patent 6,414,126, 2002.

Horton D., 1981, Carbohydr. Res., 94, 27, 10.1016/S0008-6215(00)85593-7

Deshpande, P. P.; Ellsworth, B. A.; Singh, J.; Denzel, T. W.; Lai, C.; Crispino, G.; Randazzo, M. E.; Gougoutas, J. Z.Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors. PCT Int. Appl. WO2004063209, 2004;

2004, Chem. Abstr., 141, 89317

Czernecki S., 1989, J. Org. Chem., 54, 610, 10.1021/jo00264a020

Ellsworth B. A., 2003, Tetrahedron: Asymmetry, 14, 3243, 10.1016/j.tetasy.2003.08.007

Wood I. S., 2003, Br. J. Nutr., 89, 3, 10.1079/BJN2002763

Whaley, J.; Hagan, D.; Taylor, J.; Xin, L.; Han, S.P.; Meng, M.; Ellsworth, B.; Sher, P.; McCann, W. G.; Biller, B.; Wetterau, J.; Washburn, W.Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats.Presented at 67th scientific sessions of the American Diabetes Association; June 22–26, 2007, Chicago, IL, Abstract 0559-P.

Katsuno K., 2007, J. Pharmacol. Exp. Ther., 320, 323, 10.1124/jpet.106.110296